![Logo of Pharmaceutical French group Sanofi-Aventis during a press conference to present the full-year 2005 results. Sanofi-Aventis announced a serie of positive drug research developments, in Paris, on February 24, 2006. Photo Logo of Pharmaceutical French group Sanofi-Aventis during a press conference to present the full-year 2005 results. Sanofi-Aventis announced a serie of positive drug research developments, in Paris, on February 24, 2006. Photo](https://c8.alamy.com/comp/2E95XFE/logo-of-pharmaceutical-french-group-sanofi-aventis-during-a-press-conference-to-present-the-full-year-2005-results-sanofi-aventis-announced-a-serie-of-positive-drug-research-developments-in-paris-on-february-24-2006-photo-by-christophe-guibbaudabacapresscom-2E95XFE.jpg)
Logo of Pharmaceutical French group Sanofi-Aventis during a press conference to present the full-year 2005 results. Sanofi-Aventis announced a serie of positive drug research developments, in Paris, on February 24, 2006. Photo
Nancy Whiting on LinkedIn: Recludix Pharma Enters into a Strategic Collaboration with Sanofi to… | 20 comments
![Paul Hudson, Chief Executive Officer of Sanofi speaks to the press at French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, central France, on June 16, 2020. The visit comes Paul Hudson, Chief Executive Officer of Sanofi speaks to the press at French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, central France, on June 16, 2020. The visit comes](https://c8.alamy.com/comp/2DFAY2T/paul-hudson-chief-executive-officer-of-sanofi-speaks-to-the-press-at-french-drugmakers-vaccine-unit-sanofi-pasteur-plant-in-marcy-letoile-near-lyon-central-france-on-june-16-2020-the-visit-comes-after-rival-pharmaceutical-company-this-weekend-announced-a-deal-to-supply-400-million-vaccine-doses-to-eu-countries-including-france-photo-by-bonypoolabacapresscom-2DFAY2T.jpg)
Paul Hudson, Chief Executive Officer of Sanofi speaks to the press at French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, central France, on June 16, 2020. The visit comes
![Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as # Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as #](https://pbs.twimg.com/media/FFgEnuYX0AMAFyN.png:large)
Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as #
![Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care](https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-press-release-collaboration-announcement-sanofi.png)
Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care
PDF - Paris2024-Press Release - Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris.pdf
![SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate](https://mma.prnewswire.com/media/2144614/Jaeyong_Ahn_CEO_of_SK_bioscience__left__Thomas_Triomphe_Head_of_Vaccines_GBU_at_Sanofi__right.jpg?p=facebook)
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate
![PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC](http://www.eortc.org/app/uploads/2021/06/Sanofi_press-release.jpg)
PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC
![Sanofi в X: „Press release: #Sanofi announces that it will acquire @ProteinSciences https://t.co/Uvipij6Bkr https://t.co/FoBXWy5xe4“ / X Sanofi в X: „Press release: #Sanofi announces that it will acquire @ProteinSciences https://t.co/Uvipij6Bkr https://t.co/FoBXWy5xe4“ / X](https://pbs.twimg.com/media/DEhiniWXcAIbYeM.jpg)